A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
for Cervical Squamous Cell Carcinoma
9 locations incl. Phoenix
Sponsor: Alentis Therapeutics AG
Sex: All·Age: 18+
Code: NCT07169734·Phase 1, Phase 2·Recruiting·Listed Sep 2025